BoulderBioMedFamily of Companies
BoulderBioLabs

May 28, 2026 · Boulder BioLabs

The Method Suitability Red Flags Inspectors Find — and How to Avoid Them

Five common 483-finding patterns around method suitability (bacteriostasis/fungistasis), and the QMS practices that prevent each one.

Method suitability (B/F) is one of the most common 483 finding categories in medical device sterility programs. Inspectors look at it because it's a clear pass/fail document — either the methodology is defended or it isn't. Here are the five things they find when it isn't.

Red Flag 1: No Method Suitability Document at All

The most common finding. A sterility test was run, a positive result was investigated, but no method suitability study exists in the QMS to validate the test method against the device material. Fix: confirm every released device family has a current method suitability on file.

Red Flag 2: Method Suitability Covers a Different Material

Engineering changed the housing from PEEK to a new polymer blend. The sterility test method didn't change. The method suitability is now 18 months stale against a material it never validated. Fix: any material change triggers an MS re-evaluation.

Red Flag 3: Method Suitability Failed and Was "Worked Around"

The original MS showed recovery failure for P. aeruginosa with direct inoculation. The team switched to filtration but didn't re-run the full MS — they just documented that filtration "would work." Fix: every method change requires a full re-validation, not a logical inference.

Red Flag 4: Method Suitability is Older Than the Device Family

The MS was run when the device was prototyped. Production-equivalent material wasn't tested. Fix: MS should reflect production materials, not engineering builds.

Red Flag 5: Method Suitability Doesn't Cover All Six Indicators

USP <71> specifies six indicator organisms. The MS only ran four (skipped C. sporogenes and A. brasiliensis for "convenience"). Fix: run all six per USP <71>.

How Boulder BioLabs Helps

Method suitability is bundled into every sterility program by default. We won't release a sterility result against a stale or missing MS — not to save a week.

Audit your method suitability coverage

Request a Quote →

Related Articles

FDA's 2025 Endotoxin Testing Guidance: What It Says, What It Means, and What's Actually New
Current FDA endotoxin guidance status, where it's moving on rFC and CSF-contact limits, and what to do now.
What Changed in ISO 11135:2024 — and Why Your EO Validation Probably Needs Revisiting
The 2024 revision tightened bioburden monitoring, annual revalidation, adoption studies, and MPQ language. What it means for your EO validation package.
Bioburden Trending Best Practices: Spotting Process Drift Before It Becomes a Sterility Failure
A practical bioburden trending discipline for QA managers running quarterly monitoring — action limits, investigation triggers, and the most common drift causes.